These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15894838)

  • 1. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
    Asai M; Monkawa T; Marumo T; Fukuda S; Tsuji M; Yoshino J; Kawachi H; Shimizu F; Hayashi M; Saruta T
    Hypertens Res; 2004 Dec; 27(12):971-8. PubMed ID: 15894838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
    Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
    J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.
    Zhang L; Hao JB; Ren LS; Ding JL; Hao LR
    Lab Invest; 2014 Aug; 94(8):839-50. PubMed ID: 24862968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
    Tylicki L; Renke M; Rutkowski P; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2008; 42(4):381-8. PubMed ID: 19230172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat.
    Leader CJ; Wilkins GT; Walker RJ
    PLoS One; 2021; 16(11):e0260554. PubMed ID: 34843581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan prevents the progression of mesangioproliferative nephritis in rats.
    Nakamura T; Obata J; Onizuka M; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
    Kidney Int Suppl; 1997 Dec; 63():S226-8. PubMed ID: 9407466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S; Bigazzi R; Campese VM
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S; Bigazzi R; Campese VM
    Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
    Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Kidney Int; 2007 Nov; 72(9):1164-5. PubMed ID: 17943159
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats.
    Matsumoto K; Morishita R; Moriguchi A; Tomita N; Yo Y; Nishii T; Nakamura T; Higaki J; Ogihara T
    Hypertension; 1999 Aug; 34(2):279-84. PubMed ID: 10454454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.
    Lin SL; Chen YM; Chien CT; Chiang WC; Tsai CC; Tsai TJ
    J Am Soc Nephrol; 2002 Dec; 13(12):2916-29. PubMed ID: 12444210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis.
    Kramer AB; van der Meulen EF; Hamming I; van Goor H; Navis G
    Kidney Int; 2007 Mar; 71(5):417-24. PubMed ID: 17213874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.